Content about AstraZeneca

July 16, 2013

Walgreens on Tuesday named Mark Lelinski as its new corporate VP, market access. Lelinski will be responsible for contracting and pricing strategies; the integration efforts across Walgreens pharmacy, health and wellness division; overseeing sales and account management; and managing the continued evolution of the company’s managed market strategies.

DEERFIELD Ill. — Walgreens on Tuesday named Mark Lelinski as its new corporate VP, market access. Lelinski will be responsible for contracting and pricing strategies; the integration efforts across Walgreens pharmacy, health and wellness division; overseeing sales and account management; and managing the continued evolution of the company’s managed market strategies.  

He joined Walgreens on June 17.

July 9, 2013

Mylan has received tentative approval for a generic version of a cholesterol drug made by AstraZeneca, according to Food and Drug Administration records.

SILVER SPRING, Md. — Mylan has received tentative approval for a generic version of a cholesterol drug made by AstraZeneca, according to Food and Drug Administration records.

The FDA gave the tentative approval to Mylan's rosuvastatin calcium tablets in the 5 mg, 10 mg, 20 mg and 40 mg strengths. The drug is a generic version of AstraZeneca's Crestor, which had sales of $5.1 billion in 2012, according to IMS Health.

June 10, 2013

Anglo-Swedish drug maker AstraZeneca will pay up to $1.15 billion for a U.S. developer of drugs for respiratory diseases, AstraZeneca said Monday.

LONDON — Anglo-Swedish drug maker AstraZeneca will pay up to $1.15 billion for a U.S. developer of drugs for respiratory diseases, AstraZeneca said Monday.

The company announced that it would buy Redwood City, Calif.-based Pearl Therapeutics, which has an inhaled drug for chronic obstructive pulmonary disease, called PT003 (formoterol fumarate; glycopyrrolate), in late-stage clinical development.

June 7, 2013

Actavis is hoping to become the first to market generic versions of a contraceptive and a sedative, the drug maker said.

PARSIPPANY, N.J. — Actavis is hoping to become the first to market generic versions of a contraceptive and a sedative, the drug maker said.

June 5, 2013

South Korean drug maker Hanmi Pharmaceutical Co. and U.S. partner Amneal Pharmaceuticals have made an agreement in federal court concerning a generic heartburn drug.

SEOUL, South Korea — South Korean drug maker Hanmi Pharmaceutical Co. and U.S. partner Amneal Pharmaceuticals have made an agreement in federal court concerning a generic heartburn drug that they said clears a major hurdle to its launch.

May 30, 2013

There can't be too many tried-and-true, immediate-action calcium carbonate formulations among heartburn remedies, no matter how many proton-pump inhibitors dot that shelf's landscape. At least that's what Bayer Consumer is counting on with its line extension of Alka Seltzer Fruit Chews.

There can't be too many tried-and-true, immediate-action calcium carbonate formulations among heartburn remedies, no matter how many proton-pump inhibitors dot that shelf's landscape. At least that's what Bayer Consumer is counting on with its line extension of Alka Seltzer Fruit Chews.

May 28, 2013

Anglo-Swedish drug maker AstraZeneca will buy Omthera Pharmaceuticals for $323 million, the two companies said.

PRINCETON, N.J. — Anglo-Swedish drug maker AstraZeneca will buy Omthera Pharmaceuticals for $323 million, the two companies said Tuesday.

Omthera, based in Princeton, N.J., develops drugs for dyslipidemia, conditions that result in abnormal levels of lipids in the blood. Its lead products include Epanova, an experimental drug for patients with high triglycerides that's based on omega-3 fatty acids; Omthera has finished late-stage clinical trials of the drug and plans to file for Food and Drug Administration approval in mid-2013.

May 28, 2013

A federal court has blocked Actavis from distributing its generic version of a drug for treating asthma, the company said.

PARSIPPANY, N.J. — A federal court has blocked Actavis from distributing its generic version of a drug for treating asthma, the company said.

Actavis said the U.S. Court of Appeals for the Federal Circuit had issued an injunction against Actavis' distribution of budesonide inhalation suspension at the request of AstraZeneca, which sells the drug under the trade name Pulmicort Respules.

May 22, 2013

The Food and Drug Administration has approved a generic heart disease drug made by Sandoz, the company said.

PRINCETON, N.J. — The Food and Drug Administration has approved a generic heart-disease drug made by Sandoz, the company said Wednesday.

Sandoz, the generics division of Swiss drug maker Novartis, announced the approval of candesartan cilexetil tablets, a generic version of AstraZeneca's Atacand.

The drug is used to treat some types of heart failure in adults with left ventricular systolic dysfunction, as well as high blood pressure in adults and children as young as 1.

Atacand had sales of $120.3 million in 2012, according to IMS Health.

May 22, 2013

Generic drug maker Par Pharmaceutical Cos. has started shipping an authorized generic version of a heart-disease medication made by AstraZeneca.

WOODCLIFF LAKE, N.J. — Generic drug maker Par Pharmaceutical Cos. has started shipping an authorized generic version of a heart-disease medication made by AstraZeneca.

Par said it had entered into an agreement with AstraZeneca to supply authorized generic Atacand (candesartan cilexetil) and had begun shipping the drug in the 4 mg, 8 mg, 16 mg and 32 mg strengths. Atacand has annual sales of about $113 million, according to IMS Health, and is used to treat certain kinds of heart failure and high blood pressure in children and adults.

May 21, 2013

Impax Labs has launched an authorized generic drug for migraine headaches under a partnership with AstraZeneca, Impax said.

HAYWARD, Calif. — Impax Labs has launched an authorized generic drug for migraine headaches under a partnership with AstraZeneca, Impax said.

Impax said its generics division, Global Pharmaceuticals, began shipping authorized generic zolmitriptan tablets and orally disintegrating tablets in the 2.5 mg and 5 mg strengths. The drug is a version of AstraZeneca's Zomig.

Zomig had sales of about $196 million during the 12-month period that ended in April, according to IMS Health.

May 13, 2013

Drug maker AstraZeneca is encouraging patients with asthma to control their disease and learn about how it may be affecting their lives as part of National Asthma and Allergy Awareness Month, which takes place in May.

WILMINGTON, Del. — Drug maker AstraZeneca is encouraging patients with asthma to control their disease and learn about how it may be affecting their lives as part of National Asthma and Allergy Awareness Month, which takes place in May.

May 3, 2013

Actavis' had $1.9 billion in sales in first quarter 2013, the drug maker said.

PARSIPPANY, N.J. — Actavis' had $1.9 billion in sales in first quarter 2013, the drug maker said.

The latest figure represented a 24% increase from first quarter 2012's $1.52 billion. "The new Actavis is off to a strong start in 2013, and as a result, we are increasing our 2013 forecast based on the strong performance and execution against our objectives to date," president and CEO Paul Bisaro said.

April 8, 2013

An experimental drug developed by AstraZeneca for rheumatoid arthritis produced mixed results in measurements of patients' conditions, according to results of a late-stage clinical trial.

NEW YORK — An experimental drug developed by AstraZeneca for rheumatoid arthritis produced mixed results in measurements of patients' conditions, according to results of a late-stage clinical trial.

AstraZeneca announced initial results of the phase-3 "OSKIRA-1" trial of fostamatinib, which it calls the first oral spleen tyrosine kinase inhibitor in development for RA.

April 2, 2013

A court has ruled in favor of generic drug maker Actavis concerning its generic version of a drug to treat asthma in children, the company said.

PARSIPPANY, N.J. — A court has ruled in favor of generic drug maker Actavis concerning its generic version of a drug to treat asthma in children, the company said.

March 25, 2013

Generic drug maker Actavis has reached a deal with AstraZeneca that will allow it to launch a version of a drug used to treat cholesterol in three years, Actavis said Monday.

PARSIPPANY, N.J. — Generic drug maker Actavis has reached a deal with AstraZeneca that will allow it to launch a version of a drug used to treat cholesterol in three years, Actavis said Monday.

Under a deal to settle a patent-infringement lawsuit, Actavis will be allowed to launch its generic version of Crestor (rosuvastatin calcium) tablets in the 5-mg, 10-mg, 20-mg and 40-mg strengths 67 days before July 8, 2016, when the drug's market exclusivity for use in children expires, at a fee of 39% of net sales to AstraZeneca.

March 22, 2013

AstraZeneca will pay $420 million to Moderna Therapeutics in a deal to develop drugs for a variety of diseases using a technology developed by Moderna, AstraZeneca said.

NEW YORK — AstraZeneca will pay $420 million to Moderna Therapeutics in a deal to develop drugs for a variety of diseases using a technology developed by Moderna, AstraZeneca said.

March 4, 2013

The Centers for Disease Control and Prevention set the stage for the first quadrivalent influenza vaccine to be introduced in the 2013-2014 flu season, according to a report in The Wall Street Journal.

NEW YORK — The Centers for Disease Control and Prevention last week set the stage for the first quadrivalent influenza vaccine to be introduced in the 2013-2014 flu season, according to a report in The Wall Street Journal

Quadrivalent vaccines will contain two A strains and two B strains of flu. The triumvirate vaccines in use today contain two A strains and one B strain of flu. 

February 28, 2013

Canadian generic drug makers expressed dismay over a new plan to reduce reimbursements for a half-dozen generic medications in most of the country's provinces. According to published reports, a group of premiers had reached a coordinated deal to reduce the prices their governments paid for six generic drugs, hoping to save the provinces nearly $100 million.

Canadian generic drug makers expressed dismay over a new plan to reduce reimbursements for a half-dozen generic medications in most of the country's provinces. According to published reports, a group of premiers had reached a coordinated deal to reduce the prices their governments paid for six generic drugs, hoping to save the provinces nearly $100 million.

February 25, 2013

The generic drug tidal wave became a tsunami in 2012, with some of the world's top-selling pharmaceuticals swamped by generic competition, and health plan payers scrambling to reap billions of dollars in financial savings.

The generic drug tidal wave became a tsunami in 2012, with some of the world's top-selling pharmaceuticals swamped by generic competition, and health plan payers scrambling to reap billions of dollars in financial savings.

January 28, 2013

U.S. generic drug maker Amneal Pharmaceuticals has entered a deal with South Korean drug maker Hanmi Pharmaceutical to acquire exclusive distribution rights for a Hanmi drug used for treating gastroesophageal reflux disease, Amneal said Monday.

BRIDGEWATER, N.J. — U.S. generic drug maker Amneal Pharmaceuticals has entered a deal with South Korean drug maker Hanmi Pharmaceutical to acquire exclusive distribution rights for a Hanmi drug used for treating gastroesophageal reflux disease, Amneal said Monday.

January 25, 2013

Canada's provincial and territorial governments have reached a deal that they said would save money on drugs, but that generic drug makers said had left them "disappointed."

NEW YORK — Canada's provincial and territorial governments have reached a deal that they said would save money on drugs, but that generic drug makers said had left them "disappointed."

January 17, 2013

The Food and Drug Administration on Wednesday approved Protein Sciences' Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology.

SILVER SPRING, Md. — The Food and Drug Administration on Wednesday approved Protein Sciences' Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. 

January 17, 2013

Out of more than 200,000 entries, Procter & Gamble named "William R." of Pennsylvania winner of the ultimate sports pack as part of Wild American Flavor Sweepstakes sponsored by Prilosec OTC Wildberry.

CINCINNATI — Out of more than 200,000 entries, Procter & Gamble named "William R." of Pennsylvania winner of the ultimate sports pack as part of Wild American Flavor Sweepstakes sponsored by Prilosec OTC Wildberry.

The contestant won a once-in-a-lifetime trip to three of the country’s "most flavorful" cities that host the biggest sporting events in America, including tickets to the Super Bowl, NASCAR's Daytona 500 and the NCAA basketball championship game in Atlanta, travel and accommodations and $5,000. 

January 8, 2013

Abbott Labs has spun off its specialty drug division into a new company called AbbVie, which the new company's leaders heralded Wednesday by ringing the first opening bell of 2013 at the New York Stock Exchange.

NEW YORK — Abbott Labs has spun off its specialty drug division into a new company called AbbVie, which the new company's leaders heralded Wednesday by ringing the first opening bell of 2013 at the New York Stock Exchange.